The secondary aim of this review is to compare rates of cardiovascular and cerebrovascular events (heart failure, myocardial infarction, stroke), successful clinical control (normalised or improved BP, tapering of antihypertensive medications), biochemical control (normalised plasma renin and potassium levels), as well as improved quality of life and renal function between patients who underwent adrenalectomy and those treated with MR antagonists. The gene discussed is REN; the disease is myocardial infarction.